Anzalone Christopher Richard's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed May 5, 2023
- Accession no.
- 0001628280-23-016223
- Filed
- May 5, 2023
- Trade date
- May 3-4, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $4.13M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anzalone Christopher RichardCIK 0001423029 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 3, 2023 | Common Stock | MOption exerciseAcquired | +54,928 | $2.01 | +$110,405.28 | 3,816,266 | Direct | |
| May 3, 2023 | Common Stock | SSaleDisposed | −54,928 | $39.14F2 | −$2,149,881.92 | 3,761,338 | Direct | |
| May 4, 2023 | Common Stock | MOption exerciseAcquired | +50,000 | $2.01 | +$100,500 | 3,811,338 | Direct | |
| May 4, 2023 | Common Stock | SSaleDisposed | −24,008 | $38.97F3 | −$935,591.76 | 3,787,330 | Direct | |
| May 4, 2023 | Common Stock | SSaleDisposed | −25,992 | $40.02F4 | −$1,040,199.84 | 3,761,338 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 3, 2023 | Common Stock | MOption exerciseDisposed | −54,928 | $0.00 | $0 | 516,980 | Direct | |
| May 4, 2023 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 466,980 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.47 to $39.47, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.48 to $40.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.